Skip to main content

Table 1 Study characteristics

From: Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis

Author

Year

Group

N

Age

M/F

Disease

LVEF (%)

Dose

Route

Follow-up

Imaging

Bartolucci

2015

BMNC

12

58 ± 14

9/3

DCM

≤ 40

8.19 × 106

IC

–

ECHO

Control

11

57 ± 11

8/3

Bartolucci

2017

BMSC

15

57.33 ± 10.05

12/3

DCM

≤ 40

1 × 106

IV

12 months

ECHO

Control

15

57.2 ± 11.64

14/1

Chang

2010

BMNC

12

38.6 ± 9.8

16/8

DCM

–

2 × 108

IM

6 months

ECHO

Control

12

Chen

2006

BMSC

22

59.3 ± 6.8

19/3

IDCM

< 40

5 × 106

IC

12 months

SPECT

Control

62

57.8 ± 7.2

21/2

Chen

2008

BMNC

71

53 ± 15

44/17

DCM

< 45

–

IC

24 months

ECG

Control

187

54 ± 13

136/51

Hamshere

2015

BMNC

15

57.67 ± 12.32

10/5

DCM

< 40

2.16 × 108

IC

12 months

CMR

Control

14

54.87 ± 10.86

9/6

Heldman

2014

BMNC

19

57.1 ± 10.6

18/1

IDCM

< 50

–

IM

12 months

CMR

Control

10

61.3 ± 9.0

10/0

Henry

2014

Ixmyelocel-T

39

64.7 ± 9

21/0

IDCM

< 30

2.95 × 108

IM

12 months

ECG/SPECT

Control

20

63.2 ± 12

9/0

Martino

2015

BMNC

82

49.6 ± 11.1

53/25

NIDCM

< 35

2.36 × 108

IC

12 months

ECHO

Control

78

51 ± 1.11

60/22

Nesteruk

2017

BMNC

114

66.7 ± 8.3

105/9

IDCM

< 45

3.9 × 106

IM

4–14 years

ECHO

Control

36

68.6 ± 5.78

22/4

Patel

2016

Ixmyelocel-T

59

65.3 ± 8.49

55/3

IDCM

< 35

–

IM

12 months

ECHO

Control

55

64.7 ± 9.94

45/6

Perin

2004

BMNC

11

56.5 ± 7.8

9/2

DCM

< 40

–

IM

12 months

SPECT

Control

9

58.9 ± 7.6

8/1

Sant’Anna

2014

BMNC

15

48.3 ± 8.71

13/7

NIDCM

< 35

1.06 × 108

IM

12 months

ECHO/CMR

Control

9

51.6 ± 7.79

5/4

Seth

2010

BMNC

41

45 ± 15

33/8

DCM

< 40

1.68 × 108

IC

36 months

ECHO

Control

40

49 ± 9

35/4

Song

2008

BMSC

27

  

DCM

< 50

2 × 106

IM

6 months

Ultrasound

Control

25

  

Vrtovec

2011

BMSC

28

52 ± 8

26/2

DCM

< 30

1.13 × 108

IC

12 months

ECHO

Control

28

54 ± 7

23/4

Vrtovec

2013

BMSC

55

53 ± 8

45/10

DCM

< 30

–

IC

60 months

ECHO

Control

55

55 ± 7

44/11

Wang

2006

BMSC

12

54 ± 11.1

9/3

DCM

< 45

5.86 × 105

IC

12 months

ECHO

Control

12

58.4 ± 11

8/4

Xiao

2017

BMNC

16

49.5 ± 11.6

9/7

DCM

< 40

5.1 × 108

IC

3 months

SPECT

BMSC

17

51.6 ± 12.2

12/5

Control

20

54.4 ± 11.6

14/6

Yan

2012

BMSC

18

58 ± 9.9

12/6

DCM

< 40

1 × 108

IC

12 months

SPECT/ECHO

Control

20

58.2 ± 9.8

14/6

  1. M/F male/female, LVEF left ventricular ejection fraction, IC intracoronary, IM intramyocardial, IV intravenous, QS quality assessment, BMNC bone marrow mononuclear cells, BMSC bone mesenchymal stem cells, DCM dilated cardiomyopathy, IDCM ischemic dilated cardiomyopathy, NIDCM non-ischemia dilated cardiomyopathy, ICM ischemic cardiomyopathy, CCC Chagas cardiomyopathy, CMR cardiovascular magnetic resonance imaging, ECHO echocardiography, ECG electrocardiogram, SPECT single-photon emission-computed tomography